Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Lipid-Antigen Presentation and Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CD1b drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD1b-B2M Heterodimer / Recombinant Protein Co-expressed in HEK293 for native glycosylation and stable lipid-cavity formation. High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View CD1b Products |
| Gene Delivery | CD1b Promise-ORF / Lentivirus Full-length ORF for stable cell line generation to support lipid loading and TCR activation assays. |
View CD1b Products |
| Benchmark Ab | Anti-CD1b Recombinant Antibody Recombinant positive control for flow cytometry, blocking, and immunohistochemistry applications. |
View CD1b Products |
| Validator | CD1b siRNA Set For target knockdown verification and assay specificity validation. |
View CD1b Products |
| Related Target A | B2M (Beta-2-Microglobulin) Essential light chain for stable CD1b surface expression and structural integrity. |
View B2M Products |
| Related Target B | CD1d Related CD1 family member presenting glycolipids to NKT cells; critical for cross-reactivity and selectivity screening. |
View CD1d Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Structural Instability of Monomeric CD1b | HEK293 co-expressed CD1b-B2M heterodimer preserves the native lipid-binding groove conformation. |
| Cross-reactivity within CD1 Family | Full CD1 family panel (CD1a, CD1c, CD1d) available for strict counter-screening. |
| Lack of Controls | Clinical benchmark antibodies (biosimilars) included for assay calibration. |
| False Positives | Validated siRNA included for target-specific knockdown verification. |
Live CD1b R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CD1b therapeutics is intensifying, with major players shifting focus from traditional mAbs to lipid-reactive T-cell receptor (TCR-T) therapies and diagnostic platforms for infectious diseases. As first-generation immunotherapies reach the clinic, the next wave of R&D is targeting CD1b-restricted lipid presentation to treat intracellular bacterial infections (such as Mycobacterium tuberculosis) and specific T-cell malignancies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| TCR-T / TCR-like Abs | Academic Institutes, Biotech Startups | Tuberculosis, T-ALL | Lipid-loaded CD1b-B2M complexes for TCR binding assays (Need high-purity heterodimers) |
| Monoclonal Antibodies | Oncology Biotechs | T-cell Lymphoma | Internalization and ADCC assays (Need stable CD1b-expressing lentiviral host cells) |
| Lipid-based Vaccines | Infectious Disease Consortia | Tuberculosis Prevention | In vitro lipid loading and presentation assays (Need endotoxin-controlled recombinant proteins) |